Type 1 Diabetes Drug Market by Form (Insulin Therapy, Oral Medication), End User (Drugstore, Hospital) - Global Forecast 2024-2030

Type 1 Diabetes Drug Market by Form (Insulin Therapy, Oral Medication), End User (Drugstore, Hospital) - Global Forecast 2024-2030


The Type 1 Diabetes Drug Market size was estimated at USD 17.57 billion in 2023 and expected to reach USD 19.14 billion in 2024, at a CAGR 9.06% to reach USD 32.24 billion by 2030.

Global Type 1 Diabetes Drug Market

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Type 1 Diabetes Drug Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Type 1 Diabetes Drug Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Type 1 Diabetes Drug Market, highlighting leading vendors and their innovative profiles. These include Astellas Pharma Inc., AstraZeneca PLC, B. Braun Melsungen AG, Biocon Limited, DAIICHI SANKYO COMPANY, LIMITED, Eli Lilly and Company, GSK plc, Johnson & Johnson Services, Inc., Novartis AG, Novo Nordisk A/S, Pfizer Inc., Samsung Bioepis Co., Ltd., Sanofi S.A., Teva Pharmaceutical Industries Ltd., and XOMA Corporation.

Market Segmentation & Coverage

This research report categorizes the Type 1 Diabetes Drug Market to forecast the revenues and analyze trends in each of the following sub-markets:

Form
Insulin Therapy
Long-Acting Insulin

Premix Analogs

Rapid Acting Insulin
Oral Medication
Biguanides
Metformine

Metformine Extended-Release

Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors
Canaglifozine

Dapagliflozine

Empagliflozine

Ertugliflozine
End User
Drugstore
Hospital
Region
Americas
Argentina

Brazil

Canada

Mexico

United States
California

Florida

Illinois

New York

Ohio

Pennsylvania

Texas
Asia-Pacific
Australia

China

India

Indonesia

Japan

Malaysia

Philippines

Singapore

South Korea

Taiwan

Thailand

Vietnam
Europe, Middle East & Africa
Denmark

Egypt

Finland

France

Germany

Israel

Italy

Netherlands

Nigeria

Norway

Poland

Qatar

Russia

Saudi Arabia

South Africa

Spain

Sweden

Switzerland

Turkey

United Arab Emirates

United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.
2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Type 1 Diabetes Drug Market?
2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Type 1 Diabetes Drug Market?
3. What are the technology trends and regulatory frameworks in the Type 1 Diabetes Drug Market?
4. What is the market share of the leading vendors in the Type 1 Diabetes Drug Market?
5. Which modes and strategic moves are suitable for entering the Type 1 Diabetes Drug Market?

Note: PDF & Excel + Online Access - 1 Year


1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Type 1 Diabetes Drug Market, by Region
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Growing incidences of type 1 diabetes globally
5.1.1.2. Increasing healthcare expenditure with rising disposable income
5.1.1.3. Rising patient awareness on type 1 diabetes treatment
5.1.2. Restraints
5.1.2.1. Patent expiration of drugs
5.1.3. Opportunities
5.1.3.1. Emerging introduction of novel drugs to treat diabetes
5.1.3.2. Surge in research and development activities for type 1 anti-diabetic drugs
5.1.4. Challenges
5.1.4.1. Strict regulations for the approval drugs
5.2. Market Segmentation Analysis
5.3. Market Trend Analysis
5.4. Cumulative Impact of High Inflation
5.5. Porter’s Five Forces Analysis
5.5.1. Threat of New Entrants
5.5.2. Threat of Substitutes
5.5.3. Bargaining Power of Customers
5.5.4. Bargaining Power of Suppliers
5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework
6. Type 1 Diabetes Drug Market, by Form
6.1. Introduction
6.2. Insulin Therapy
6.3.1. Long-Acting Insulin
6.3.2. Premix Analogs
6.3.3. Rapid Acting Insulin
6.3. Oral Medication
6.4.1. Biguanides
6.4.2.1. Metformine
6.4.2.2. Metformine Extended-Release
6.4.2. Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors
6.4.3.1. Canaglifozine
6.4.3.2. Dapagliflozine
6.4.3.3. Empagliflozine
6.4.3.4. Ertugliflozine
7. Type 1 Diabetes Drug Market, by End User
7.1. Introduction
7.2. Drugstore
7.3. Hospital
8. Americas Type 1 Diabetes Drug Market
8.1. Introduction
8.2. Argentina
8.3. Brazil
8.4. Canada
8.5. Mexico
8.6. United States
9. Asia-Pacific Type 1 Diabetes Drug Market
9.1. Introduction
9.2. Australia
9.3. China
9.4. India
9.5. Indonesia
9.6. Japan
9.7. Malaysia
9.8. Philippines
9.9. Singapore
9.10. South Korea
9.11. Taiwan
9.12. Thailand
9.13. Vietnam
10. Europe, Middle East & Africa Type 1 Diabetes Drug Market
10.1. Introduction
10.2. Denmark
10.3. Egypt
10.4. Finland
10.5. France
10.6. Germany
10.7. Israel
10.8. Italy
10.9. Netherlands
10.10. Nigeria
10.11. Norway
10.12. Poland
10.13. Qatar
10.14. Russia
10.15. Saudi Arabia
10.16. South Africa
10.17. Spain
10.18. Sweden
10.19. Switzerland
10.20. Turkey
10.21. United Arab Emirates
10.22. United Kingdom
11. Competitive Landscape
11.1. FPNV Positioning Matrix
11.2. Market Share Analysis, By Key Player
11.3. Competitive Scenario Analysis, By Key Player
12. Competitive Portfolio
12.1. Key Company Profiles
12.1.1. Astellas Pharma Inc.
12.1.2. AstraZeneca PLC
12.1.3. B. Braun Melsungen AG
12.1.4. Biocon Limited
12.1.5. DAIICHI SANKYO COMPANY, LIMITED
12.1.6. Eli Lilly and Company
12.1.7. GSK plc
12.1.8. Johnson & Johnson Services, Inc.
12.1.9. Novartis AG
12.1.10. Novo Nordisk A/S
12.1.11. Pfizer Inc.
12.1.12. Samsung Bioepis Co., Ltd.
12.1.13. Sanofi S.A.
12.1.14. Teva Pharmaceutical Industries Ltd.
12.1.15. XOMA Corporation
12.2. Key Product Portfolio
13. Appendix
13.1. Discussion Guide
13.2. License & Pricing
FIGURE 1. TYPE 1 DIABETES DRUG MARKET RESEARCH PROCESS
FIGURE 2. TYPE 1 DIABETES DRUG MARKET SIZE, 2023 VS 2030
FIGURE 3. TYPE 1 DIABETES DRUG MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. TYPE 1 DIABETES DRUG MARKET SIZE, BY REGION, 2023 VS 2030 (%)
FIGURE 5. TYPE 1 DIABETES DRUG MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. TYPE 1 DIABETES DRUG MARKET DYNAMICS
FIGURE 7. TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2023 VS 2030 (%)
FIGURE 8. TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 9. TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2023 VS 2030 (%)
FIGURE 10. TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 11. AMERICAS TYPE 1 DIABETES DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 12. AMERICAS TYPE 1 DIABETES DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 13. UNITED STATES TYPE 1 DIABETES DRUG MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 14. UNITED STATES TYPE 1 DIABETES DRUG MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 15. ASIA-PACIFIC TYPE 1 DIABETES DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 16. ASIA-PACIFIC TYPE 1 DIABETES DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 17. EUROPE, MIDDLE EAST & AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 18. EUROPE, MIDDLE EAST & AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 19. TYPE 1 DIABETES DRUG MARKET, FPNV POSITIONING MATRIX, 2023
FIGURE 20. TYPE 1 DIABETES DRUG MARKET SHARE, BY KEY PLAYER, 2023

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings